Jiangsu Kanion Pharmaceutical Co.
Jiangsu Kanion Pharmaceutical Co.
Jiangsu Kanion Pharmaceutical Co. | Date: 2017-03-08
Disclosed is a novel anti-enterovirus 71 (EV71) 1,2,5-thiadiazolidine-1,1-dioxide derivative or a pharmaceutically acceptable salt thereof, and specifically, a compound represented by formula (II) or a pharmaceutically acceptable salt thereof.
News Article | April 21, 2017
— Neurodegenerative Disorders Drug Development Pipeline Review, 2017 market report says Small molecule drugs dominate the pipeline, with approximately 64% of total pipeline molecules. In comparison, the number of biologics in the pipeline is much lower, representing approximately 26% of the pipeline. Overall the neurodegenerative disorders pipeline is large, with a substantial proportion of products being early-stage assets at the Preclinical development stage. Browse the 200 Tables and Figures, Spread across 797 Pages Report Available at http://www.reportsnreports.com/contacts/discount.aspx?name=964827. There are over 1,400 products in active development in the neurodegenerative disorders therapy area. The current market landscape consists of a number of biologics and small molecules, while the pipeline also consists of gene therapies and cell therapies, demonstrating broader pharmaceutical research and development. The report provides comprehensive information on the pipeline development landscape for is Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Amyotrophic lateral sclerosis and Multiple sclerosis, from Discovery through to the Pre-registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field. Scope of The Report • Which companies are the most active within the pipeline for neurodegenerative disorders? • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication? • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? • What are the most important R&D milestones and data publications to have happened in this disease area? Alzheimer's Disease – Pipeline for AB Science SA, AbbVie Inc, AC Immune SA, Accera, Inc., Acelot, Inc., Actinogen Limited, Acumen Pharmaceuticals, Inc., Addex Therapeutics Ltd, Affibody AB, AFFiRiS AG, Alector LLC, Alkermes Plc, Allergan Plc, Allinky Biopharma, ALSP, Inc., Alzhyme Pty Ltd, Alzinova AB, AlzProtect SAS, Amarantus Bioscience Holdings, Inc., Amgen Inc., Anavex Life Sciences Corp., Aphios Corporation, Apodemus AB, Applied Research using OMIC Sciences, S.L., Araclon Biotech, S.L., Archer Pharmaceuticals, Inc., ArmaGen Inc., Artery Therapeutics, Inc., AskAt Inc., Astellas Pharma Inc., AstraZeneca Plc, Asubio Pharma Co., Ltd., Ausio Pharmaceuticals, LLC, Avineuro Pharmaceuticals, Inc., Axon Neuroscience SE, Axovant Sciences Ltd., Axsome Therapeutics, Inc., Axxam SpA, Beactica AB, Berg LLC, BioArctic Neuroscience AB, Bioasis Technologies Inc., Biogen Inc, Biomar Microbial Technologies, Bionature E.A. Ltd., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Bsim2, Cardax Pharmaceuticals, Inc., Carna Biosciences, Inc., Celon Pharma Sp. z o.o., CHA Bio & Diostech Co., Ltd., Chase Pharmaceuticals Corporation, Clera Inc., Cognition Therapeutics, Inc., Cognosci, Inc., CohBar, Inc., Connexios Life Sciences Pvt. Ltd., ContraVir Pharmaceuticals, Inc., Corium International, Inc., Coronis Partners Ltd., Cortice Biosciences, Inc., Critical Outcome Technologies Inc., Crossbeta Biosciences B.V., D-Pharm Ltd., Daewoong Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Daval International Limited, DermaXon, LLC, Dongkook Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly and Company, Emergent BioSolutions Inc., EncephRx, Inc., Endece, LLC, ENKAM Pharmaceuticals A/S, Ensemble Therapeutics Corporation, Ensol Biosciences Inc., Epigen Biosciences, Inc., Euroscreen S.A., Evotec AG, F. Hoffmann-La Roche Ltd., FORUM Pharmaceuticals Inc., Genentech, Inc., Genervon Biopharmaceuticals, LLC, GlaxoSmithKline Plc, GliaCure Inc., Glialogix, Inc., Golden Biotechnology Corp., Grifols, S.A., H. Lundbeck A/S, Heptares Therapeutics Limited, HitGen LTD, Humanetics Corporation, Ichor Medical Systems, Inc., Icure Pharmaceutical Inc., Immungenetics AG, Impel NeuroPharma, Inc., ImStar Therapeutics Inc., Inovio Pharmaceuticals, Inc., IntelGenx Corp., Intellect Neurosciences, Inc., Intra-Cellular Therapies, Inc., INVENT Pharmaceuticals, Inc., Io Therapeutics, Inc., Iproteos S.L., Jeil Pharmaceutical Co. Ltd., Jiangsu Kanion Pharmaceutical Co.Ltd., Johnson & Johnson, K-Stemcell Co.Ltd., Kadmon Corporation, LLC, Kalgene Pharmaceuticals Inc., Kareus Therapeutics, SA, KineMed, Inc., Krenitsky Pharmaceuticals Inc., Kyowa Hakko Kirin Co.Ltd., Lead Discovery Center GmbH, Les Laboratoires Servier SAS, Lipopharma Therapeutics SL, Living Cell Technologies Limited, Lupin Limited, M3 Biotechnology, Inc., ManRos Therapeutics, MedDay SA, Medestea Research & Production S.p.A., MedImmune, LLC, Medisyn Technologies, Inc., MEDRx Co.Ltd., Merck & Co.Inc., Metabolic Solutions Development Company, LLC Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=964827. List of Tables Number of Products under Development for Alzheimer's Disease 28 Number of Products under Development for Alzheimer's Disease – Comparative Analysis 29 Comparative Analysis by Late Stage Development, Alzheimer's Disease 85 Comparative Analysis by Clinical Stage Development, Alzheimer's Disease 86 Alzheimer's Disease – Pipeline by AB Science SA, 158 Alzheimer's Disease – Pipeline by AbbVie Inc, 159 List of Figures Number of Products under Development for Alzheimer's Disease 28 Number of Products under Development for Alzheimer's Disease – Comparative Analysis 29 Comparative Analysis by Late Stage Development, Alzheimer's Disease 85 Comparative Analysis by Clinical Stage Development, Alzheimer's Disease 86 Number of Products by Top 10 Mechanism of Actions, Alzheimer's Disease 556 Assessment by Monotherapy Products, Amyotrophic Lateral Sclerosis 585 In Depth Table of Content for Neurodegenerative Disorders Drug Development Pipeline Review, 2017 About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.reportsnreports.com/reports/964827-neurodegenerative-disorders-drug-development-pipeline-review-2017.html